An integrated microfluidic chip for immunomagnetic detection and isolation of rare prostate cancer cells from blood.

An integrated microfluidic chip for immunomagnetic detection and isolation of rare prostate cancer cells from blood.

Biomed Microdevices. 2016 Feb;18(1):22

Authors: Esmaeilsabzali H, Beischlag TV, Cox ME, Dechev N, Parameswaran AM, Park EJ

Abstract
The quantitative and qualitative analysis of circulating tumor cells (CTCs) has the potential to improve the clinical management of several cancers, including prostate cancer. As such, there is much interest in the isolation of CTCs from the peripheral blood of cancer patients. We report the design, fabrication, and proof-of-principle testing of an integrated permalloy-based microfluidic chip for immunomagnetic isolation of blood-borne prostate cancer cells using an antibody targeting prostate surface membrane antigen (PSMA). The preliminary results using spiked blood samples indicate that the proposed device is consistently capable of isolating prostate cancer cells with high sensitivity (up to 98 %) at clinically relevant low concentrations (down to 20 cells/mL) and an acceptable throughput (100 μL/min).

PMID: 26876965 [PubMed - as supplied by publisher]

from Head and Neck on PubMed via xlomafota13 on Inoreader http://ift.tt/20Bberd
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1OdTV8z
via IFTTT